DUNAD THERAPEUTICS LTD.

• ◆

  Material uncertainty over going concern

  The directors appreciate the challenging nature of drug discovery and with the relatively short cash runway and the uncertain status of additional fundraising acknowledge a material uncertainty exists in relation to the ability of the Group and parent company to continue as a going concern. The current cash balance and the convertible loan note proceeds provide a cash runway beyond 12 months from the date of filing the financial statements and thus management believes a going concern basis of preparation remains appropriate.

• ◆

  2 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

• ·

  Going-concern uncertainty disclosed

• ·

  Negative shareholders' funds

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. DUNAD THERAPEUTICS LTD. 2020-08-14 → present
2. WARHEAD LTD 2020-04-02 → 2020-08-14

Accounting basis

FRS 102

Reporting scope

Consolidated group

Abridged

Yes — abridged accounts (limited disclosure)

Auditor

Price Bailey LLP

Audit opinion

Unaudited (audit-exempt)

Going concern

Material uncertainty disclosed

“The directors appreciate the challenging nature of drug discovery and with the relatively short cash runway and the uncertain status of additional fundraising acknowledge a material uncertainty exists in relation to the ability of the Group and parent company to continue as a going concern. The current cash balance and the convertible loan note proceeds provide a cash runway beyond 12 months from the date of filing the financial statements and thus management believes a going concern basis of preparation remains appropriate.”

Group structure

1. DUNAD THERAPEUTICS LTD. · parent
   1. Dunad Therapeutics US. Inc. 100% · USA · Research and experimental development on biotechnology
   2. 2740376 Ontario Inc 100% · Canada · Holding company
   3. 2752591 Ontario Inc. 100% · Canada · Holding company
   4. 2692372 Ontario Inc. 100% · Canada · Holding company

Significant events

• “In August 2025, the Company successfully completed a further round of funding from some of its existing investors in the form of a convertible loan note, committing up to £6.0 million of further investment. Of this balance, £2.0 million was received on 12 August 2025 and a further £0.9 million was received in April 2026.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

15

last 12 months

Capital events

11

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.